Janssen gets pri­or­i­ty re­view for prostate can­cer com­bo; Im­muno­Gen re­ports Q1 Ela­here sales

Janssen’s com­bi­na­tion ther­a­py of ni­ra­parib with abi­raterone ac­etate plus pred­nisone for the treat­ment of BCRA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) is mov­ing along.

Jannsen post­ed on Twit­ter on Fri­day morn­ing that its sub­mis­sion to the FDA for the com­bi­na­tion ther­a­py has re­ceived a pri­or­i­ty re­view. The drug com­bo was sub­mit­ted for an NDA back in March.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.